Intravitreal injection of ranibizumab during cataract surgery in patients with diabetic macular edema

Paulo I. Rauen, Jefferson A.S. Ribeiro, Felipe P.P. Almeida, Ingrid Scott, André Messias, Rodrigo Jorge

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

PURPOSE: To investigate macular thickness and visual acuity changes after 1 intravitreal injection of 0.5-mg ranibizumab during phacoemulsification cataract surgery in eyes with diabetic macular edema refractory to laser treatment. METHODS: Eleven eyes of 11 patients with diabetic macular edema refractory to modified Early Treatment Diabetic Retinopathy Study laser therapy received intravitreal during phacoemulsification cataract surgery. Comprehensive ophthalmic evaluation was performed preoperatively and at 1, 4, 8 ± 1, and 12 ± 2 weeks postoperatively. Main outcome measures included central subfield thickness and best-corrected Early Treatment Diabetic Retinopathy Study visual acuity. RESULTS: Eleven patients completed the 12-week study visit. Mean central subfield thickness (±SEM) was 399.82 ± 29.50 μm at baseline and did not change significantly at any postoperative study visit (P > 0.05). Mean (±SEM) best-corrected Early Treatment Diabetic Retinopathy Study visual acuity was 0.95 ± 0.13 logarithm of the minimum angle of resolution (20/200) at baseline and was significantly improved at Weeks 1 (0.38 ± 0.13), 4 (0.38 ± 0.11), 8 (0.35 ± 0.08), and 12 (0.46 ± 0.12) after treatment (P < 0.05). CONCLUSION: In this case series of patients with diabetic macular edema refractory to laser therapy, intravitreal ranibizumab administered during cataract surgery was associated with no significant change in central subfield thickness postoperatively. Significant improvement in best-corrected Early Treatment Diabetic Retinopathy Study visual acuity was observed after treatment, likely because of cataract removal.

Original languageEnglish (US)
Pages (from-to)1799-1803
Number of pages5
JournalRetina
Volume32
Issue number9
DOIs
StatePublished - Oct 1 2012

Fingerprint

Intravitreal Injections
Macular Edema
Cataract
Diabetic Retinopathy
Visual Acuity
Phacoemulsification
Laser Therapy
Therapeutics
Ranibizumab
Lasers
Outcome Assessment (Health Care)

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Rauen, Paulo I. ; Ribeiro, Jefferson A.S. ; Almeida, Felipe P.P. ; Scott, Ingrid ; Messias, André ; Jorge, Rodrigo. / Intravitreal injection of ranibizumab during cataract surgery in patients with diabetic macular edema. In: Retina. 2012 ; Vol. 32, No. 9. pp. 1799-1803.
@article{e422f220b3f94831a55afe006b3fd5e3,
title = "Intravitreal injection of ranibizumab during cataract surgery in patients with diabetic macular edema",
abstract = "PURPOSE: To investigate macular thickness and visual acuity changes after 1 intravitreal injection of 0.5-mg ranibizumab during phacoemulsification cataract surgery in eyes with diabetic macular edema refractory to laser treatment. METHODS: Eleven eyes of 11 patients with diabetic macular edema refractory to modified Early Treatment Diabetic Retinopathy Study laser therapy received intravitreal during phacoemulsification cataract surgery. Comprehensive ophthalmic evaluation was performed preoperatively and at 1, 4, 8 ± 1, and 12 ± 2 weeks postoperatively. Main outcome measures included central subfield thickness and best-corrected Early Treatment Diabetic Retinopathy Study visual acuity. RESULTS: Eleven patients completed the 12-week study visit. Mean central subfield thickness (±SEM) was 399.82 ± 29.50 μm at baseline and did not change significantly at any postoperative study visit (P > 0.05). Mean (±SEM) best-corrected Early Treatment Diabetic Retinopathy Study visual acuity was 0.95 ± 0.13 logarithm of the minimum angle of resolution (20/200) at baseline and was significantly improved at Weeks 1 (0.38 ± 0.13), 4 (0.38 ± 0.11), 8 (0.35 ± 0.08), and 12 (0.46 ± 0.12) after treatment (P < 0.05). CONCLUSION: In this case series of patients with diabetic macular edema refractory to laser therapy, intravitreal ranibizumab administered during cataract surgery was associated with no significant change in central subfield thickness postoperatively. Significant improvement in best-corrected Early Treatment Diabetic Retinopathy Study visual acuity was observed after treatment, likely because of cataract removal.",
author = "Rauen, {Paulo I.} and Ribeiro, {Jefferson A.S.} and Almeida, {Felipe P.P.} and Ingrid Scott and Andr{\'e} Messias and Rodrigo Jorge",
year = "2012",
month = "10",
day = "1",
doi = "10.1097/IAE.0b013e31824bebb8",
language = "English (US)",
volume = "32",
pages = "1799--1803",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

Intravitreal injection of ranibizumab during cataract surgery in patients with diabetic macular edema. / Rauen, Paulo I.; Ribeiro, Jefferson A.S.; Almeida, Felipe P.P.; Scott, Ingrid; Messias, André; Jorge, Rodrigo.

In: Retina, Vol. 32, No. 9, 01.10.2012, p. 1799-1803.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intravitreal injection of ranibizumab during cataract surgery in patients with diabetic macular edema

AU - Rauen, Paulo I.

AU - Ribeiro, Jefferson A.S.

AU - Almeida, Felipe P.P.

AU - Scott, Ingrid

AU - Messias, André

AU - Jorge, Rodrigo

PY - 2012/10/1

Y1 - 2012/10/1

N2 - PURPOSE: To investigate macular thickness and visual acuity changes after 1 intravitreal injection of 0.5-mg ranibizumab during phacoemulsification cataract surgery in eyes with diabetic macular edema refractory to laser treatment. METHODS: Eleven eyes of 11 patients with diabetic macular edema refractory to modified Early Treatment Diabetic Retinopathy Study laser therapy received intravitreal during phacoemulsification cataract surgery. Comprehensive ophthalmic evaluation was performed preoperatively and at 1, 4, 8 ± 1, and 12 ± 2 weeks postoperatively. Main outcome measures included central subfield thickness and best-corrected Early Treatment Diabetic Retinopathy Study visual acuity. RESULTS: Eleven patients completed the 12-week study visit. Mean central subfield thickness (±SEM) was 399.82 ± 29.50 μm at baseline and did not change significantly at any postoperative study visit (P > 0.05). Mean (±SEM) best-corrected Early Treatment Diabetic Retinopathy Study visual acuity was 0.95 ± 0.13 logarithm of the minimum angle of resolution (20/200) at baseline and was significantly improved at Weeks 1 (0.38 ± 0.13), 4 (0.38 ± 0.11), 8 (0.35 ± 0.08), and 12 (0.46 ± 0.12) after treatment (P < 0.05). CONCLUSION: In this case series of patients with diabetic macular edema refractory to laser therapy, intravitreal ranibizumab administered during cataract surgery was associated with no significant change in central subfield thickness postoperatively. Significant improvement in best-corrected Early Treatment Diabetic Retinopathy Study visual acuity was observed after treatment, likely because of cataract removal.

AB - PURPOSE: To investigate macular thickness and visual acuity changes after 1 intravitreal injection of 0.5-mg ranibizumab during phacoemulsification cataract surgery in eyes with diabetic macular edema refractory to laser treatment. METHODS: Eleven eyes of 11 patients with diabetic macular edema refractory to modified Early Treatment Diabetic Retinopathy Study laser therapy received intravitreal during phacoemulsification cataract surgery. Comprehensive ophthalmic evaluation was performed preoperatively and at 1, 4, 8 ± 1, and 12 ± 2 weeks postoperatively. Main outcome measures included central subfield thickness and best-corrected Early Treatment Diabetic Retinopathy Study visual acuity. RESULTS: Eleven patients completed the 12-week study visit. Mean central subfield thickness (±SEM) was 399.82 ± 29.50 μm at baseline and did not change significantly at any postoperative study visit (P > 0.05). Mean (±SEM) best-corrected Early Treatment Diabetic Retinopathy Study visual acuity was 0.95 ± 0.13 logarithm of the minimum angle of resolution (20/200) at baseline and was significantly improved at Weeks 1 (0.38 ± 0.13), 4 (0.38 ± 0.11), 8 (0.35 ± 0.08), and 12 (0.46 ± 0.12) after treatment (P < 0.05). CONCLUSION: In this case series of patients with diabetic macular edema refractory to laser therapy, intravitreal ranibizumab administered during cataract surgery was associated with no significant change in central subfield thickness postoperatively. Significant improvement in best-corrected Early Treatment Diabetic Retinopathy Study visual acuity was observed after treatment, likely because of cataract removal.

UR - http://www.scopus.com/inward/record.url?scp=84866937120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866937120&partnerID=8YFLogxK

U2 - 10.1097/IAE.0b013e31824bebb8

DO - 10.1097/IAE.0b013e31824bebb8

M3 - Article

C2 - 22495327

AN - SCOPUS:84866937120

VL - 32

SP - 1799

EP - 1803

JO - Retina

JF - Retina

SN - 0275-004X

IS - 9

ER -